The Heart -- In an unusually long follow-up of patients from one of cardiology's most influential trials, implantable cardioverter defibrillator (ICD) therapy in a primary-prevention population continued to cut away at mortality four to eight years after implantation, even compared with already-significant survival gains in the earlier years.
